Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

CHRONIC MYELOGENOUS LEUKEMIA

Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Pfirrmann M, Clark RE, Prejzner W, Lauseker M, Baccarani M, Saussele S, et al. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia. 2020;34:2138–49.

    Article  Google Scholar 

  2. 2.

    Pfirrmann M, Baccarani M, Saussele S, Guilhot F, Cervantes F, Ossenkoppele G, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30:48–56.

    CAS  Article  Google Scholar 

  3. 3.

    Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84.

    CAS  Article  Google Scholar 

  4. 4.

    Molica M, Canichella M, Alunni Fegatelli D, Colafigli G, Massaro F, Latagliata R, et al. The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials. Am J Hematol. 2017;92:e661–e664.

    Article  Google Scholar 

  5. 5.

    Geelen IGP, Sandin F, Thielen N, Janssen JJWM, Hoogendoorn M, Visser O, et al. Validation of the EUTOS long-term survival score in a recent independent cohort of “real world” CML patients. Leukemia. 2018;32:2299–303.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Massimo Breccia.

Ethics declarations

Conflict of interest

MB received honoraria from Novartis, Incyte, Pfizer, BMS/Celgene, AbbVie; PP received honoraria from Novartis, Incyte, Pfizer; FC received honoraria from Novartis, BMS, Pfizer, Incyte; GS received honoraria from Novartis, Incyte, Pfizer; all the others declare no conflict of interest

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Breccia, M., Pregno, P., Castagnetti, F. et al. Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study. Leukemia 35, 1814–1816 (2021). https://doi.org/10.1038/s41375-021-01292-4

Download citation

Search

Quick links